PETALING JAYA: Good news for patients who could not afford an exorbitant medicine for an aggressive type of breast cancer.
The Health Ministry has approved the biosimilar version of trastuzumab (a monoclonal antibody), a targeted therapy, for women with HER2-positive breast cancer patients, said Dr Dzulkefly Ahmad.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
